The following information will be used to determine eligibility for this study. Fill out the form and click “Preview Message.” This will draft an email you can send directly to the Research Coordinator. Please note, this does not guarantee
entry into this particular study.
* indicates required field
Personal Information
Add more details about who you are and how you would like to be contacted (e.g. phone, text, email).
This two-part observational study will look at the effects of CFTR modulators on growth in young children with CF. These drugs are intended to help CFTR protein function closer to normal.
Clinical trials that test potential drugs and therapies in people with cystic fibrosis are a major part of CF research. They take place at Cystic Fibrosis Foundation-accredited care centers all over the United States and enroll people with CF of all ages.
Nothing is more important than patient safety in developing new treatments for cystic fibrosis. The U.S. government requires that all clinical trials are supervised for safety, and the Cystic Fibrosis Foundation adds additional measures to protect study volunteers.
The following is a collection of information and news about Trikafta™, the triple-combination modulator therapy that was approved by the U.S. Food and Drug Administration on Oct. 21, 2019.
DONATE
GET INVOLVED
